How do GLP-1s affect bone health? New studies investigate
Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial,” published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies.
STAT+: Omada reports first profitable quarter as it seizes broad GLP-1 opportunity
Virtual chronic care company Omada, which went public less than a year ago, reported a quarterly profit for the first time.
GLP-1 Drugs May Prevent, Treat Multiple Addictions
(MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower risks of several substance use disorders (SUDs) in adults with type 2 diabetes, according to a target trial emulation using data on veterans.
In patients without a history…
Roche partner Zealand posts Phase 2 data for amylin obesity drug
Zealand Pharma is out with the Phase 2 data for an amylin analog that spurred one of the industry’s largest-ever obesity drug deals last year.
The drug, called petrelintide, led to up to 10.7% mean …
Ozempic-style drugs could slash complication risks after heart attacks, research suggests
Weight-loss drugs may prevent deadly heart complications by opening blocked blood vessels after heart attacks, groundbreaking new research reveals.
Ozempic, Wegovy May Help Reverse Damage Caused by Osteoarthritis
A new study found that semaglutide benefits extend beyond weight loss by easing osteoarthritis symptoms. Tatsiana Volkava/Getty Images
A new study reports that GLP-1 semaglutide medications may help reverse the effects of osteoarthritis in the joints.
The researchers say the drugs accomplish this by repairing tissue damage by reprogramming cells that maintain healthy cartilage.
Eli Lilly’s new program aims to boost employer coverage of GLP-1s
With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers’ GLP-1 treatments.
The pharma giant on Thursday announced the launch of …
Study: Weight regain after GLP-1s plateaus below starting weight
A new study has reinforced that GLP-1 receptor agonists are unlikely to produce durable weight loss, but indicates that rather than returning to the starting weight, individual weight gain will plateau at 75.5% of the weight lost.
Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity
THURSDAY, March 5, 2026 — Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a review published online March 4 in eClinicalMedicine.Brajan…